People

Management

Mikael Lindstam

CEO & BOARDMEMBER

Mikael has been involved in start-up operations and development programs that have generated investments totalling more than 250 million Swedish kroners from business, private and public capital. Mikael has, among other things, been involved and developed Galecto Biotech AB and Gabather AB from Forskarpatent’s project portfolio, where he also carried out a number of licence deals and IP-sales. In order to focus on the company, Mikael recently finalised his employment as head of business development at Forskarpatent’s and Innovationpatent’s holding company as patent and license portfolio. Mikael holds a PhD in inorganic chemistry as well as having further education within marketing, entrepreneurship and resource management.

Kjell G Stenberg

CMO & CHAIRMAN OF THE BOARD

Kjell has a background as partner to Medwell Capital Corp, COO of BioMS Medical Corp, which brought 200 million USD from investors through license deals. Kjell founded Combio A/S in 2001 and acted as CEO. From 1975 to 2000, Kjell worked as senior researcher and director at Astra/AstraZeneca, where he contributed to bringing various drugs into the market as head of research and development. Kjell’s current directorships and executive positions are; Accequa AB (CEO), Celus Parmaceuticals Ltd, USA (CEO), Galecto AB (board member), PCI Biotech Holding (publicly listed company, board member), Biomedical Development Europe (owner), and Novation Pharmaceuticals Inc., Canada (board member). Kjell holds a PhD within medical science.

Ola Skanung

CFO

Master of business and economics with many years of experience as CFO and working with start-ups and growth projects within the private as well as with state and regional development actors.

Luiza Jedlina

CSO

As a former project leader in the Forkarpatent fund, Luiza was a key person in order to establish the study that indicated the proposed drug candidates and development path for a commercial therapeutic product. Aside from her three years as consultant, Luiza has 15 years of scientific experience within cell biology, immunology, haematology, epidemiology and biochemistry as well as developer of vaccines against parasites. Luiza has worked as a visiting researcher and coordinator in several EU-funded research projects and has developed new methods for experimental and analytical biochemistry. She is also a co-inventor to two patents. Luiza holds a PhD in molecular parasitology and immunology and also holds MSc in toxicology.

Ulf Björklund

Programme Manager

Ulf has more than 30 years of experience in drug development from both large and small companies. From 1983 to 2002 Ulf worked with clinical research at Kabi Pharmacia AB / Pharmacia & Upjohn / Pharmacia where he held management positions. From 2002 to 2010, Ulf was CEO of OxyPharma AB and between 2010 and 2016, CEO of Aprea AB. Today Ulf runs his own company as a consultant with a focus on drug development and project management in Life Science. Ulf’s current board assignments are; Lipum AB (Chairman of the Board), Wnt Research AB, Annexin Pharmaceuticals AB and TikoMed AB (Board member). Ulf holds a M.Sc. in Pharmacy degree from Uppsala University.

Erika Medin

Programme Coordinator & Communication Specialist

Erika has more than 20 years experience from research oriented companies within the pharmaceutical industry, including Perstorp Pharma and AstraDraco/AstraZeneca. Over the years, Erika has had various positions within administration, communication and project management. She has a Bachelor of Arts degree from Lund University and a Communications diploma from IHM Business School. Erika runs her own consultant business, specializing in project management and communications with a focus on small research companies in Life Science.

Lina Gustavsson

OFFICE MANAGER

Lina has several years of experience in service and administration. She has a diploma in Quality and Environmental Management Systems, and has for several years helped companies to develop and manage structured management systems. At Aptahem Lina is responsible for office management.

BOARD OF DIRECTORS

Kjell G Stenberg

CMO & CHAIRMAN OF THE BOARD

Kjell has a background as partner to Medwell Capital Corp, COO of BioMS Medical Corp, which brought 200 million USD from investors through license deals. Kjell founded Combio A/S in 2001 and acted as CEO. From 1975 to 2000, Kjell worked as senior researcher and director at Astra/AstraZeneca, where he contributed to bringing various drugs into the market as head of research and development. Kjell’s current directorships and executive positions are; Accequa AB (CEO), Celus Parmaceuticals Ltd, USA (CEO), Galecto AB (board member), PCI Biotech Holding (publicly listed company, board member), Biomedical Development Europe (owner), and Novation Pharmaceuticals Inc., Canada (board member). Kjell holds a PhD within medical science.

Cristina Glad

BOARD MEMBER

Cristina Glad has and more than 25 years’ experience in research and business development in biotechnology and drug development. She has worked on projects that include the development and production processes of antibody drugs. Cristina Glad has also been involved in research and development collaborations with both biotechnology and pharmaceutical companies, and the in- and out-licensing of projects. In her role as both CEO and Vice President of BioInvent International AB she was involved in the development of the company. Since December 2013, she has worked as a consultant in her own company. Cristina Glad is a member of the Royal Swedish Academy of Engineering Sciences (IVA), she has a PhD in biochemistry and an E*MBA.

Theresa Comiskey Olsen

BOARD MEMBER

Theresa Comiskey Olsen, Attorney at Law (USA), is a Partner at Langseth Law Firm in Oslo, Norway. Theresa has been with Langseth since January 2016 after starting her own practice with focus on legal transactions in the Life Sciences/Biotech field. Prior to starting her practice in 2008, she was General Counsel of Nycomed, which has since been acquired by Takeda. Theresa continues to grow her practice at Langseth with focus on legal transactions in the Life Sciences/Biotech field. She has her B.A. from University of Pennsylvania and her J.D. from University of Detroit Mercy School of Law.

Johan Lindh

BOARD MEMBER

With over 20 years in academia, Johan Lindh has worked as a molecular biologist and has held several positions in parasitology, at the Infectious Diseases Institute (SMI) / Karolinska Institute. Collaboration with Lund University arose after the identification, and early indications of the anticoagulant properties, of Aptahem’s drug candidate were shown. This resulted in a patent application that formed the basis Aptahem’s drug development. Since January 2014 Johan Lindh has been an associate professor of microbiology at the Institute of Cell and Molecular Biology, Microbiology, Uppsala University.

Mikael Lindstam

CEO & BOARD MEMBER

Mikael has been involved in start-up operations and development programs that have generated investments totalling more than 100 million Swedish kroners from business, private and public capital. Mikael has, among other things, been involved and developed Galecto Biotech AB and Gabather AB from Forskarpatent’s project portfolio, where he also carried out a number of licence deals and IP-sales. In order to focus on the company, Mikael recently finalised his employment as head of business development at Forskarpatent’s and Innovationpatent’s holding company as patent and license portfolio. Mikael holds a PhD in inorganic chemistry as well as having further education within marketing, entrepreneurship and resource management.